

Special Issue

Research in MicroRNA Profiling of Prostate Cancer (Volume II)

Message from the Guest Editors

Prostate cancer (PCa) is the most common non-cutaneous cancer with a high mortality rate among men in the Western world. Despite the advancements in the management of PCa, there are still many clinical challenges that need to be tackled. Both the detection and treatment monitoring of PCa still rely on prostate-specific antigen (PSA) as the main biomarker for the disease. Nevertheless, both the diagnostic and prognostic values of PSA are quite limited due to its low sensitivity and specificity. MicroRNAs (miRNAs) seem to be quite promising alternative biomarkers in this context. However, the exact role of PCa-specific miRNAs in the prevention, diagnosis, and treatment of PCa needs to be clarified. In this second edition of our Special Issue (Research in MicroRNA Profiling of Prostate Cancer), we would like to continue to explore the role of miRNAs as potential alternative diagnostic, predictive, and prognostic biomarkers for PCa.

Guest Editors

Prof. Dr. Palle Jörn Sloth Østher

Department of Urology, Vejle Hospital (Lillebaelt Hospital), University Hospital of Southern Denmark, 7100 Vejle, Denmark

Dr. Ahmed H. Zedan

Department of Oncology, Vejle Hospital (Lillebaelt Hospital), University Hospital of Southern Denmark, 7100 Vejle, Denmark

Deadline for manuscript submissions

closed (30 June 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/183175

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)